Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Chris Molineaux
Observed institution:
Calithera (United States)
ORCID:
0000-0001-7737-0593
Observed ORCID:
0000-0001-7737-0593
OpenAlex ID:
A5084995152
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
2021
·
James J. Harding
, Melinda Telli
, et al.
·
Clinical Cancer Research
·
93
Safety and Antitumor Efficacy of the Proteasome Inhibitor Carfilzomib (PR-171) Dosed for Five Consecutive Days in Hematologic Malignancies: Phase 1 Results.
2007
·
Robert Z. Orlowski
, Keith Stewart
, et al.
·
Blood
·
25
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
2016
·
Andreas Lundqvist
, Vincent van Hoef
, et al.
·
Journal for ImmunoTherapy of Cancer
·
11
PDF
Supplementary Data from A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
2024
·
James J. Harding
, Melinda Telli
, et al.
Data from A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
2024
·
James J. Harding
, Melinda Telli
, et al.
Show more works
View as search
Works count:
6
Citation count:
140
H-index:
4
I10-index:
4
Year
Topic
Type
